用来抵抗季节性流感的疫苗对于可能大流行的流感病毒A的新亚型的效果不佳,此外,预计(大流行)流感疫苗的免疫原性差,这可以通过使用佐剂来克服。已证实可用于人的佐剂有限,有必要选择安全的和有效的能够增强流感疫苗的免疫原性和诱导广泛保护性的T细胞应答的佐剂。本文中,作者评估了新的纳米颗粒-G3,其作为小鼠模型的季节性三价灭活病毒疫苗的佐剂。G3佐剂分添加和不添加甜菊糖苷(DT,为二萜类)两种配方,使用两种 Vaccines to combat seasonal flu are not very effective against new subtypes of the pandemic influenza virus A and, in addition, the immunogenicity of the (pandemic) flu vaccine is expected to be poor, which can be overcome by the use of adjuvants. Adjuvants have proven limited to use in humans and it is necessary to choose safe and effective adjuvants that enhance the immunogenicity of the influenza vaccine and induce a broadly protective T cell response. Here, the authors evaluated a new nanoparticle-G3, which is an adjuvant to the seasonal trivalent inactivated virus vaccine of the mouse model. G3 adjuvant with and without stevia added (DT, diterpene) two formulations, the use of two